No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years

American Journal of Hematology

Volumn 86, Issue 6, 2011, Pages 479-483

  Kastritis, Efstathios ^b   Kyrtsonis, Marie Christine ^b   Hatjiharissi, Evdoxia ^b   Symeonidis, Argiris ^b   Michalis, Eurydiki ^b   Repoussis, Panagiotis ^b   Tsatalas, Konstantinos ^b   Michael, Michael ^b   Sioni, Anastasia ^b   Kartasis, Zafiris ^b   Stefanoudaki, Ekaterini ^b   Voulgarelis, Michael ^b   Delimpasi, Sosana ^b   Gavriatopoulou, Maria ^b   Koulieris, Efstathios ^b   Gika, Dimitra ^b   Vervesou, Elissavet ^b   Konstantopoulos, Konstantinos ^b   Kokkini, Garyfalia ^b   Zomas, Athanasios ^b   Roussou, Paraskevi ^b   Anagnostopoulos, Nikolaos ^b   Economopoulos, Theofanis ^b   Terpos, Evangelos ^b   Zervas, Konstantinos ^b   Dimopoulos, Meletios A ^a   more..

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; NUCLEOSIDE ANALOG; RITUXIMAB;

ADULT; AGED; ARTICLE; CAUSE SPECIFIC SURVIVAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT OUTCOME; WALDENSTROEM MACROGLOBULINEMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY IMPROVEMENT; SURVIVAL RATE; TREATMENT OUTCOME; WALDENSTROM MACROGLOBULINEMIA;

EID: 79956137322     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22027     Document Type: Article

References (28)

1. Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP. Diagnosis and management of Waldenstrom's macroglobulinemia. J Clin Oncol 2005; 23: 1564-1577.
2. Ghobrial IM, Fonseca R, Gertz MA, et al. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol 2006; 133: 158-164.
3. Dhodapkar MV, Hoering A, Gertz MA, et al. Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003. Blood 2009; 113: 793-796.
4. Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 2009; 113: 4163-4170.
5. Kyle RA, Greipp PR, Gertz MA, et al. Waldenstrom's macroglobulinaemia: A prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol 2000; 108: 737-742.
6. Dimopoulos MA, Kantarjian H, Estey E, et al. Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med 1993; 118: 195-198.
7. Dimopoulos MA, Kantarjian H, Weber D, et al. Primary therapy of Waldenstrom's macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol 1994; 12: 2694-2698.
8. Dimopoulos MA, O'Brien S, Kantarjian H, et al. Fludarabine therapy in Waldenstrom's macroglobulinemia. Am J Med 1993; 95: 49-52.
9. Dimopoulos MA, Zervas C, Zomas A, et al. Treatment of Waldenstrom's macroglobulinemia with rituximab. J Clin Oncol 2002; 20: 2327-2333.
10. Gertz MA, Rue M, Blood E, et al. Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 2004; 45: 2047-2055.
11. Treon SP, Emmanouilides C, Kimby E, et al. Extended rituximab therapy in Waldenstrom's macroglobulinemia. Ann Oncol 2005; 16: 132-138.
12. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 2007; 25: 3344-3349.
13. Chen CI, Kouroukis CT, White D, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: A phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1570-1575.
14. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Treatment of relapsed or refractory Waldenstrom's macroglobulinemia with bortezomib. Haematologica 2005; 90: 1655-1658.
15. Treon SP, Hunter ZR, Matous J, et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: Results of WMCTG Trial 03-248. Clin Cancer Res 2007; 13: 3320-3325.
16. Dimopoulos MA, Zomas A, Viniou NA, et al. Treatment of Waldenstrom's macroglobulinemia with thalidomide. J Clin Oncol 2001; 19: 3596-3601.
17. Treon SP, Soumerai JD, Branagan AR, et al. Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood 2008; 112: 4452-4457.
18. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008; 111: 2521-2526.
19. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-2520.
20. Kastritis E, Zervas K, Symeonidis A, et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): An analysis of the Greek Myeloma Study Group (GMSG). Leukemia 2009; 23: 1152-1157.
21. Liu Q, Fayad L, Cabanillas F, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 Years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 2006; 24: 1582-1589.
22. Swenson WT, Wooldridge JE, Lynch CF, et al. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 2005; 23: 5019-5026.
23. Fisher RI, LeBlanc M, Press OW, et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005; 23: 8447-8452.
24. Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30: 116-120.
25. Kristinsson SY. Patterns of survival in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia: A population-based study of 1, 555 patients diagnosed in Sweden from 1980 to 2005. Venice: IWWM-6; 2010.
26. Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol 2009; 27: 3830-3835.
27. Kastritis E, Kyrtsonis MC, Hadjiharissi E, et al. Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH). Leuk Res 2010; 34: 1340-1343.
28. Dimopoulos MA, Kastritis E, Delimpassi S, et al. The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens. Haematologica 2008; 93: 1420-1422.